Anthony Elias, MD

Recognitions

• Member, AOA (1980)
  
• Best Doctor for Executives, ColoradoBiz Magazine (2012)
  Named Best Doctor for Oncology and Hematology, Breast Cancer, Lung Cancer, Stem Cell Transplant and Sarcomas.
• Top Doctor, US News & World Report (2011)
• Top Doctor in Newsweek, Castle Connolly (2015)
• Foundations in Medicine Golden Stethoscope Award for Patient/Physician Communication, University of Colorado School of Medicine (2014)
• Top Doctor in Oncology, Castle Connolly (2017)

Research Interests

Clinical trials

Publications

• Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 Feb 16;30(4):729-740. PubMed PMID: 38109213
• O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R Jr, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024 Aug 30;12(8). PubMed PMID: 39214650
• Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3737-3747. PubMed PMID: 39277672
• Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER /Her2- breast cancer. NPJ Breast Cancer. 2024 Oct 6;10(1):88. PubMed PMID: 39368973
• Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3728-3736. PubMed PMID: 39277671
• Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL. Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. J Clin Oncol. 2024 Apr 20;42(12):1450-1453. PubMed PMID: 38478799
• Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. PubMed PMID: 39019058
• Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clin Cancer Res. 2023 Dec 18. [Epub ahead of print] PubMed PMID: 38109213
• Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 3;15(15). PubMed PMID: 37568766
• Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 Jun;21(6):594-608. PubMed PMID: 37308117
• Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER /HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20;9(1):41. PubMed PMID: 37210417
• Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 Aug 1;83(15):2543-2556. PubMed PMID: 37205634
• Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 May;185:69-82. PubMed PMID: 36965330
• Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 Mar 20;41(9):1725-1734. PubMed PMID: 36469840
• Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 1;8(1):128. PubMed PMID: 36456573
• Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 Nov;176:155-163. PubMed PMID: 36215947
• Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 Sep 20;40(27):3205-3221. PubMed PMID: 35759724
• Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. PubMed PMID: 35714673
• Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10;8(1):62. PubMed PMID: 35538119
• Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 Aug;33(8):814-823. PubMed PMID: 35513244
• Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 Jul 1;28(13):2762-2770. PubMed PMID: 35486638
• Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 Aug 1;40(22):2479-2490. PubMed PMID: 35394800
• Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 Mar;61(3):359-371. PubMed PMID: 34856027
• Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 Apr 20;40(12):1291-1300. PubMed PMID: 34260265
• Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. PubMed PMID: 34143979
• Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol. 2021 Aug 20;39(24):2720-2731. PubMed PMID: 34003702
• Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Mol Cancer Ther. 2021 Jun;20(6):1062-1071. PubMed PMID: 33722849
• Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 Mar 15;127(6):894-904. PubMed PMID: 33231866
• Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 May 1;19(5):484-493. PubMed PMID: 34794122
• Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2( ) breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 Nov 5;12(1):6428. PubMed PMID: 34741023
• Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 5;7(1):131. PubMed PMID: 34611148
• Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 1;7(11):1654-1663. PubMed PMID: 34529000
• Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2021 Dec 2. [Epub ahead of print] PubMed PMID: 34856027
• Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 May 1;19(5):484-493. PubMed PMID: 34794122
• Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2( ) breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 Nov 5;12(1):6428. PubMed PMID: 34741023
• Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 5;7(1):131. PubMed PMID: 34611148
• Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 1;7(11):1654-1663. PubMed PMID: 34529000
• Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2021 Jul 14;:JCO2003452. [Epub ahead of print] PubMed PMID: 34260265
• Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. PubMed PMID: 34143979
• Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol. 2021 Aug 20;39(24):2720-2731. PubMed PMID: 34003702
• Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Mol Cancer Ther. 2021 Jun;20(6):1062-1071. PubMed PMID: 33722849
• Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 Mar 15;127(6):894-904. PubMed PMID: 33231866
• Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1 -Mutant Breast Cancer. Cancer Res. 2021 Feb 1;81(3):732-746. PubMed PMID: 33184106
• Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2020 Nov 24. [Epub ahead of print] PubMed PMID: 33231866
• Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1 mutant breast cancer. Cancer Res. 2020 Nov 12. [Epub ahead of print] PubMed PMID: 33184106
• Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 Dec;9(23):8801-8808. PubMed PMID: 33063469
• Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 Oct;59(10):1129-1139. PubMed PMID: 32822091
• Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1355-1362. PubMed PMID: 32701140
• Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. PubMed PMID: 32259783
• Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 May 1;6(5):676-684. PubMed PMID: 32053137
• Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 Apr 1;38(10):1059-1069. PubMed PMID: 32031889
• Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. PubMed PMID: 31693129
• Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2019 Oct 31. [Epub ahead of print] PubMed PMID: 31693129
• Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 Feb;17(2):118-126. PubMed PMID: 30787125
• Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):37-48. PubMed PMID: 30267249
• Hoffner B, Elias AD, Villalobos VM. Targeted Therapies in the Treatment of Sarcomas. Target Oncol. 2018 Oct;13(5):557-565. PubMed PMID: 30143942
• Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 Sep 1;29(9):1995-2002. PubMed PMID: 30084934
• Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 Aug 2;20(1):82. PubMed PMID: 30071865
• Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 26;3(14). PubMed PMID: 30046001
• Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2018 May;16(5S):605-610. PubMed PMID: 29784737
• Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug;171(1):11-20. PubMed PMID: 29725889
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. PubMed PMID: 29523670
• Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar;25(3):768-775. PubMed PMID: 28887726
• Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Horm Cancer. 2018 Jan 16. [Epub ahead of print] PubMed PMID: 29340907
• Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces. 2018 Jan 1;161:200-209. PubMed PMID: 29080504
• Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar;25(3):768-775. PubMed PMID: 28887726
• Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces. 2018 Jan 1;161:200-209. PubMed PMID: 29080504
• Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 Sep 1;29(9):1995-2002. PubMed PMID: 30084934
• Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
• Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 Aug 2;20(1):82. PubMed PMID: 30071865
• Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2
• Hoffner B, Elias AD, Villalobos VM. Targeted therapies in the treatment of sarcomas. Targeted Oncology 2018; 13: 557-565. https://doi.org/10.1007/s11523-018-0583-0 Published online 8/24/18.
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. PubMed PMID: 29523670
• Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Horm Cancer. 2018 Apr;9(2):82-94. PubMed PMID: 29340907
• Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2018 May;16(5S):605-610. PubMed PMID: 29784737
• Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May;169(1):1-7. PubMed PMID: 29352368
• Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug;171(1):11-20. PubMed PMID: 29725889
• Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 Nov;23(6):627-629. PubMed PMID: 29112794
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 Apr;15(4):433-451. PubMed PMID: 28404755
• Elias AD. How I Manage: Adjuvant therapy in Her2-positive breast cancer. Clinical Oncology News 2017, July, p 19-23
• 84. Elias AD, Kabos P. Triple negative breast cancer: a review. Internal Medicine Review 3/2017
• 193. Gordon MA, D’Amato N, Christenson J, Babbs B, Gu H, Wulfkuhle J, Petricoin E, Elias A, Richer JK. Synergy between androgen receptor (AR)-targeting agents seviteronel (SEVI) or enzalutamide (ENZA) and mTOR or HER2 pathway-targeting agents in breast cancer. Proc AACR 2017
• 194. Gucalp A, Danso M, Elias A, Bardia A, Ali H, Potter D, Gabrail N, Haley B, Khong H, Riley E, Ervin L, Eisner J, Baskin-Bey E, Moore W, Traina TA. Phase 2 Stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor inhibitor, in women with advanced AR+ triple negative or estrogen receptor positive breast cancer: CLARITY-01. Proc ASCO 2017, A-1102
• 195. Nanda R, Liu MC, Yee D, DeMichele AM, Yau C, Asare SM, Hylton NM, van’t Veer LJ, Perlmutter J, Wallace AM, Chien J, Forero-Torres A, Ellis ED, Han HS, Clark AS, Albain KS, Boughey JC, Elias AD, Berry DA, Esserman LJ, I-SPY 2 Investigators. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. Proc ASCO 2017, A-506 (oral).
• 196. Elias A, Gucalp A, Van Poznak DH, Bardia A, Resaul A, Eisner J, Baskin-Bey E, Traina TA. Initial phase (Ph)2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in men with advanced breast cancer (BC). Proc SABCS 2017, P5-23-04, poster.
• 197. Mayordomo J, Falkson C, Kepes J, Poage GM, Israel MA, Schroeder BE, Schnabel CA, Elias A. Correlation of breast cancer index (BCI) prognostic and predictive results to clinicopathologic risk groups in early stage HR+ breast cancer. Proc SABCS 2017, P1-07-12, poster.
• 198. Elias A, Israel MA, Schroeder BE, Zhang Y, Schnabel CA, Mayordomo J. Correlation of breast cancer index (BCI) predictive (HoxB13/IL17BR) results to nodal status and hormone receptor expression in early stage HR+ breast cancer. Proc SABCS 2017, P4-09-09, poster.
• 199. Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson D, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Clinical safety and efficacy of the Aurora and angiogenic kinase inhibitot ENMD-2076 in previously treated, local advanced or metastatic triple-negative breast cancer. Proc SABCS 2017, PD3-16, poster discussion.
• 200. Chawla S, Van Tine B, Pollack S, Ganjoo K, Elias A, Riedel R, Attia S, Choy E, Okuno S, Agulnik M, Von Mehren M, Livingston M, Keedy V, Verschraegen C, Philip T, Bohac C, Lu H, Chen M, Maki R. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: interim analysis of immunogencity, tumor control and survival. Proc ESMO and CTOS 2017, in press.
• 201. Yee D, DeMichele A, Isaacs C, Symmans F, Yau C, Albain KS, Hylton NM, Forero-Torres A, van't Veer LJ, Perlmutter J, Rugo HS, Melisko M, Chen Y-Y, Balassanian R, Krings G, Datnow B, Hasteh F, Tipps A, Weidner N, Zhang H, Tickman R, Thornton S, Ritter J, Amin K, Klein M, Chen B, Keeney G, Ocal T, Feldman M, Klipfel N, Sattar H, Mueller J, Gwin K, Baker G, Kallakury B, Zeck J, Duan X, Ersahin C, Gamez R, Troxell M, Mansoor A, Grasso LeBeau L, Sams S, Wisell J, Wei S, Harada S, Vinh T, Stamatakos MD, Tawfik O, Fan F, Adams A, Rendi M, Minton S, Magliocco A, Sahoo S, Fang Y, Hirst G, Singhrao R, Asare SM, Wallace AM, Chien AJ, Ellis ED, Han HS, Clark AS, Boughey JC, Elias AD, Nanda R, Korde L, Murthy R, Lang J, Northfelt D, Khan Q, Edmiston KK, Viscusi R, Haley B, Kemmer K, Zelnak A, Berry DA, Esserman LJ. GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Proc SABCS 2017, GS3-08.
• Villalobos VM, Hoffner B, Elias AD. We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas. Cancer. 2017 Jan 1;123(1):20-24. PubMed PMID: 27696384
• Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. PubMed PMID: 28404760
• Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA. A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clin Cancer Res. 2017 Aug 1;23(15):4046-4054. PubMed PMID: 28280092
• Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Mol Cancer Ther. 2017 Jul;16(7):1389-1400. PubMed PMID: 28468774
• Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 Jul 1;77(13):3455-3466. PubMed PMID: 28512248
• Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2017 Sep 8. [Epub ahead of print] PubMed PMID: 28887726
• Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016 Jul;8(4):305-8. PubMed PMID: 27482289
• Elias AD, Wang WS, Hardesty L. A 55-Year-Old Woman With New Triple-Negative Breast Mass, Less Than 2 cm on Both Mammogram and Ultrasound. Oncology (Williston Park). 2016 Mar;30(3):258-62. PubMed PMID: 26984221
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar;14(3):324-54. PubMed PMID: 26957618
• Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. PubMed PMID: 26371143
• Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016 Mar 15;18(1):34. PubMed PMID: 26979312
• Sedjo RL, Flatt SW, Byers T, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Wyatt H, Rock CL. Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Support Care Cancer. 2016 Aug;24(8):3285-93. PubMed PMID: 26945570
• Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol. 2016 Oct;56:40-51. PubMed PMID: 27260947
• Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 Jun 10;34(17):1995-2002. PubMed PMID: 27001563
• Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. PubMed PMID: 27406346
• Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):23-34. PubMed PMID: 27406347
• Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 12. [Epub ahead of print] PubMed PMID: 27621408
• Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. PubMed PMID: 27291997
• D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 Nov;14(11):1054-1067. PubMed PMID: 27565181
• Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2016 Oct 4. [Epub ahead of print] PubMed PMID: 27702820
• Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 Dec 15;30(12). PubMed PMID: 27987198
• Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar;14(3):769-78. PubMed PMID: 25713333
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr;13(4):448-75. PubMed PMID: 25870381
• Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR or Quadruple Negative Disease. Horm Cancer. 2015 Dec;6(5-6):206-13. PubMed PMID: 26201402
• Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85. PubMed PMID: 26656517
• Demark-Wahnefried W, Colditz GA, Rock CL, Sedjo RL, Liu J, Wolin KY, Krontiras H, Byers T, Pakiz B, Parker BA, Naughton M, Elias A, Ganz PA. Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Res Treat. 2015 Nov;154(2):329-37. PubMed PMID: 26518022
• Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep;29(9):669-70, 678-9. PubMed PMID: 26384804
• Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2015 Sep 14. [Epub ahead of print] PubMed PMID: 26371143
• Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. J Clin Oncol. 2015 Oct 1;33(28):3169-76. PubMed PMID: 26282657
• DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1;21(13):2911-5. PubMed PMID: 25712686
• Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the Aorta: A systematic review and pooled analysis of published reports. Ann Vasc Surg 2014; 28: 515-525.
• Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerroero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the Androgen Receptor in Breast Cancer and Preclinical Analysis of Enzalutamide. Breast Cancer Research 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599. PMID: 24451109
• Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Feb 3. [Epub ahead of print] PMID: 24497407
• Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the Aorta: A systematic review and pooled analysis of published reports. Ann Vasc Surg 2014; 28: 515-525. PMID: 24485779
• Pathiraja TN, Nayak S, Xi Y, Jiang S, Garee JP, Edwards DP, Lee A, Shea MJ, Santen R, Gannon F, Kangaspeska S, Jelinek J, Issa J-P, Richer J, Elias A, McIlroy M, Young L, Davidson N, Normolle D, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine resistant breast cancer. Science Translational Medicine 2014, Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326. PMID: 24670685
• Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. PMID: 24881463
• Lopez JP, Gajdos C, Elias A. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun;16(6):387. doi: 10.1007/s11912-014-0387-z. PMID: 24756367
• Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr;12(4):542-90. PMID: 24717572
• Fisher C, Diamond JR, Kounalakis N, Kabos P, Mayordomo J, Rabinovitch R, Murphy C, Finlayson C, Borges VF, Elias AD. The Integration of Locoregional with Systemic Adjuvant Therapy for Early Stage Breast Cancer: the Shifting Sands of Decision Making. Breast Cancer Management 2014; 3: 1-8.
• Fisher CM, Klein C, Kondapalli L, Elias A, Borges V. Management of young breast cancer patients with de novo genetic mutations. Clinical Quandaries. Oncology 2014; Oct; 28(10). Pii: 201947. PMID: 25323616
• Traina TA, Yardley DA, Patel MR, Schwartzberg LS, Elias A, Gucalp A, Blaney ME, Gibbons J, Hudis CA, LoRusso P. A phase 1 open-label study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer. IMPAKT 2014 Breast Cancer Conference May 2014, Abstract 214.
• Gralow JR, Barlow WE, Paterson A, Lew DL, Stopeck A, Hayes DF, Hershman D, Schubert M, Clemons M, van Poznak C, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino M, Margolis J, Dakhil S, Chew H, Livingston RB, Hortobagyi GN. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery (ClinicalTrials.gov Identifier: NCT00127205). Proc ASCO 2014.
• Lin N, Gabrail N, Sarantopoulos J, Schwartzberg L, Kesari S, Bates S, Anders C, Elias A, Castaigne J-P, Iordanova V, Lawrence B, Kurzrock R. Evaluation of CNS and peripheral anti-tumor activity of ANG1005 in patients with brain metastases arising from breast tumors and other advanced solid tumors. Proc ASCO 2014.
• Trivalent Ganglioside Vaccine in Metastatic Sarcoma Patients Rendered Disease-Free by Surgery: A Randomized Phase 2 Trial. Proc ASCO 2014.
• Schwartzberg LS, Yardley DA, Elias A, Patel MR, Gucalp A, Burris HA, Peterson AC, Hannah AL, Blaney ME, Gibbons J, Tudor IC, Steinberg JL, LoRusso P, Infante JR, Hudis CA, Traina TA. Enzalutamide plus exemestane: a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. Proc ASCO 2014.
• D’Amato N, Spoelstra N, Elias A, Cox MB, Richer JK. Androgen Receptors in Estrogen Receptor Positive Breast Cancer. Endocrine Society 2014.
• Diamond JR, Tan AC, Pitts TM, van Bokhoven A, Aisner D, Elias AD, Borges VF, Miller KD, Eckhardt SG, Tentler JJ. A phase II clinical trial of ENMD-2076 in metastatic triple –negative breast cancer: translating a p53-based biomarker from bench to bedside. Proc TAT, 2014.
• Gordon MA, D’Amato N, Gu H, Elias A, Richer JK. Targeting multiple pathways in breast cancer: androgen receptor, Her2, and mTOR. Keystone Conference 2014.
• Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Elias A, Sartorius CA, Kabos P. CD146 positive and negative stroma direct breast tumor estrogen receptor levels, therapeutic response and metastatic potential. Proc SABCS 2014, P4-04-06.
• D'Amato NC, Jacobsen BM, Cochrane DR, Spoelstra NS, Babbs BL, Elias A, Richer JK. Inhibiting androgen receptor nuclear localization decreases estrogen receptor (ER) activity and tumor growth in ER+ breast cancer. Proc SABCS 2014, P3-04-06
• Gordon MA, D’Amato N, Gu H, Wong D, Elias A, Richer JK. Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR. Proc SABCS 2014, P6-03-07.
• Diamond JR, Elias AD. The Development of Targeted Therapies for Triple-Negative Breast Cancer: Can We Harness Tumor Heterogeneity to Improve Patient Outcomes. Breast Cancer Management. Breast Cancer Management 2013; 2: 175-178.
• Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun;27(6):526-7, 566. PMID: 23909065
• Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001-.
• Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer (Beyond the Basics). UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004-.
• Traina TA, Yardley, DA, Patel M, Schwartzberg L, Elias A, Gucalp A, Peterson AC, Hannah A, Gibbons J, Khondker Z, Hudis CA, LoRusso P. A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer. SABCS 2013 PD3-6 (A938), accepted, poster discussion.
• Elias A, Modi S, Krop IE, Pegram M, Ipe D, Guardino E, Althaus B, LoRusso PM. Results from a Phase 2a Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer. SABCS 2013 P4-12-09 (A1520) accepted, poster presentation.
• Lin N, Schwartzberg L, Kesari S, Elias A, Anders C, Raizer J, Kozloff, Amiri-Kordestani L. A phase II study of ANG1005, a novel, brain-penetrant taxane derivative, in breast cancer patients with brain metastases. AACR-NCI-EORTC 2013, Abstract B76/989 accepted.
• D’Amato NC, Cochrane DR, Barton VN, Thor AD, Elias AD, Richer JK Targeting the androgen receptor in multiple breast cancer subtypes, Invited symposium presentation. AACR Advances in Breast Cancer. October 2013, 1A18.
• Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, MDd, Liu E, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H, for the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group. Reducing Breast Cancer Recurrence with Weight Loss, a Vanguard Trial: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. Contemporary Clinical Trials 2013; 34: 282-295.
• Kessler ER, Elias AD. Resistance to HER2-targeted therapy in HER2+ breast cancer. Clinical Medicine Reviews in Women’s Health, Libertas Academica, 2012, in press.
• Fini, MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clinical and Translational Medicine 2012; 1: 16.
• Elias AD. Management of Small T1ab N0 Breast Cancers. Proc ASCO Educational Book 2012.
• Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001-
• Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer (Beyond the Basics). UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004-.
• Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Goddard E, Connaghan KD, Jedlicka P, Elias A, Bain D, Richer JK. microRNAs and Hormone Receptor Action in Breast Cancer. Endocrine Society 2012.
• 94. Morrow PK, Murthy FK, Ensor JE, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase II trial of Angiozyme (RPI.4610) in the treatment of metastatic breast cancer. Cancer 2012 Jan 26, epub ahead of print.
• 62. Kessler ER, Elias AD. Resistance to HER2-targeted therapy in HER2+ breast cancer. Clinical Medicine Reviews in Women’s Health, Libertas Academica, 2012, in press.
• Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 2012, epub 7/24.
• 5. Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer (Beyond the Basics). UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004-.
• 4. Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001-.
• 147. Cochrane DR, Jacobsen BM, Jean A, Elias A, Richer JK. The Role of Androgen Receptor in Postmenopausal Breast Cancer. Era of Hope 2011.
• 148. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Zojwalla NJ, Willey R, Grebennik DO. Phase II trial of anti-IGF-1R antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumor. Proc ASCO 2011; A-10004. Oral presentation.
• 149. Kabos P, Li C, Finlay-Schultz J, Kline E, Edgerton S, Wissel J, Finlayson C, Elias A, Sartorius C. A patient-derived tumor model to study hormone receptor action and luminal specific stem/progenitor cells in estrogen receptor positive breast cancer. AACR, San Francisco, October 2011.
• 150. Lu D, Modi S, Elias A, Agarwal P, Yi J-H, Guardino AE, Althaus B, Girish S. Pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and paclitaxel or docetaxel in patients with Her2-positive MBC previously treated with a trastuzumab-containing regimen. SABCS 2011.
• 59. Gadjos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol 2011; 5: 35-43.
• 60. Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF. Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park) 2011; 25: 351-356.
• 61. Borges VF, Elias AD. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. J Clin Oncol 2011; Jul 18, epub.
• 147. Cochrane DR, Jacobsen BM, Jean A, Elias A, Richer JK. The Role of Androgen Receptor in Postmenopausal Breast Cancer. Era of Hope 2011, submitted.
• 148. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Zojwalla NJ, Willey R, Grebennik DO. Phase II trial of anti-IGF-1R antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and ewing family of tumor. Proc ASCO 2011; A-81273.
• 93. Cochrane DR, Cittelly DM, Howe EH, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor alpha Status and Dicer Level in Breast Cancer. Hormones and Cancer 2011; 1: 306-319. PMID: 21761362
• 93. Cochrane DR, Cittelly DM, Howe EH, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor alpha Status and Dicer Level in Breast Cancer. Hormones and Cancer 2011, accepted.
• 56. Elias AD, Kabos P, Bowles DW. Adjuvant Treatment of Breast Cancer: Chapter 20. In: Finlayson, editor. Elsevier, 2010.
• 57. Elias AD. The Use of Molecular Profiles in the Management of Breast Cancer. In: Finlayson, editor. Elsevier, 2010.
• 58. Elias AD. Triple negative breast cancer: a short review. Am J Clin Oncol 2009 Dec 17 epub. Am J Clin Oncol 2010 Dec; 33: 637-645.
• 3. Kelly K, Elias A. Treatment of small cell carcinoma of the lung. A. Elias only author 1998-2001. Since 2002, with Dr. Karen Kelly as first author. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 1998-.
• 4. Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001-.
• 5. Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004-.
• 143. Cochrane DR, McKinsey E, Cittelly D, Spoelstra SN, Tan A-C, Elias A, Richer JK. Dicer1 is targeted by two EMT-associated microRNAs in breast cancer. Keystone Conference, 2010.
• 144. Krop IE, Modi S, Elias A, LoRusso P, Choi YJ, Lu M. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with Her2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. SABCS 2010; P3-14-10.
• 145. Lu D, Krop I, Modi S, Elias A, LoRusso P, Huang J, Lu M, Girish S. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with Her2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. SABCS 2010; P3-14-22.
• 146. Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advance triple-negative breast cancer. SABCS 2010; P6-12-02.
• Weitzel L-R B, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Singh M, Duncan MW, Elias A. Discovery and verification of protein differences between ER positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Can Res Ther 2010; Jan 20 (epub). PMID: 2087651
• Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Gralow J. A phase 2 trial of pemetrexed and gemcitabine in metastatic breast cancer in patients who have received prior taxane therapy. J Clin Oncol 2010, in press.
• 90. Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Gralow J. A phase 2 trial of pemetrexed and gemcitabine in metastatic breast cancer in patients who have received prior taxane therapy. Clin Breast Cancer 2010; 10: 148-153.
• 91. Weitzel L-R B, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Singh M, Duncan MW, Elias A. Discovery and verification of protein differences between ER positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Can Res Ther 2010; Jan 20 (epub). PMID: 2087651
• 92. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2010 Jul 28. Epub ahead of print.
• Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009.
• Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004, 2005, 2006, 2007, 2008, 2009.
• Kabos P, Dye WW, Elias A, Horwitz KB, Sartorius CA. Rare ER-/CK5+ cells in luminal type human breast cancers are resistant to hormone therapy and chemotherapy and repopulate ER+ tumors. Proc AACR 2009 (oral presentation).
• Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C, Elias A. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. Proc ASCO 2009; 27: 60s (A1081).
• Diamond JR, Amaria R, O’Donnell CI, Meltesen L, Swisshelm K, Malancon D, McGavran L, Singh M, Elias A Borges VF. The incidence of low-level HER2 gene amplification and chromosome 17 polysomy in cases of newly diagnosed breast cancer and their association with clinical prognostic markers. J Clin Oncol 2009; 27 (suppl) abstr e22012.
• Schwartz GN, Borges VF, Weiselberg LR, Elias AD, Budman DR. Lapatinib restores endocrine sensitivity in selected patients with estrogen receptor (ER) positive metastatic breast cancer. Proc SABCS 2009. Cancer Res 2009; 69 (suppl): 24: 675s (A-3089).
• Diamond JR, Finlayson CA, Thienalt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early stage BRCA-2 associated breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park) 2009; 23 (August 17).
• Elias AD. Triple negative breast cancer: a short review. Am J Clin Oncol 2009 Dec 17 epub.
• Maki RG, Keohan ML, Undevia S, Livingston M, Cooney M, Elias A, Saulle M, Wright JJ, D’Adamo DR, Schuetze S. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
• Lamont EB, Landrum MB, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, Keating NL, McNeil1 BJ for the Cancer and Leukemia Group B. Differences in Clinical Trial Patients Attributes and Outcomes According to Enrollment Setting. J Clin Oncol 2009; 11/23 epub.
• Maki RG, Keohan ML, Undevia S, Livingston M, Cooney M, Elias A, Saulle M, Wright JJ, D’Adamo DR, Schuetze S, CTEP Sorafenib Sarcoma Study Group. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. Proc ASCO 2008.
• Kabos P, Dye WW, Elias A, Sartorius CA, Horwitz KB. The chemoresistant population of luminal subtype human breast cancer cells expresses a basal phenotype. 31st San Antonio Breast Cancer Symposia, December 2008 (oral presentation).
• Harvell DME, Richer JK, Spoelstra N, Singh M, Borges V, Finlayson C, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant hormone therapy of breast cancers: dominance of tamoxifen agonist effects in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment, in press.
• Harvell DM, Spoelstra NS, Singh M, Finlayson C, Phang T, Trapp S, Hunter L, Borges VB, Elias A, Horwitz KB, Richer JK. Molecular signatures of response to neoadjuvant endocrine therapies for breast cancer. Breast Cancer Research and Treatment, in press.
• Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff, AC, Eisenberg PD, Lehman M, Adams BJ, Baum CM, Miller KD. A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, in press.
• R.G. Maki, M. L. Keohan, S. Undevia, M. Livingston, M. Cooney, A. Elias, M. Saulle, J. J. Wright, D. R. D’Adamo, S. Schuetze, CTEP Sorafenib Sarcoma Study Group. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. Proc ASCO 2008.
• Harvell DME, Richer JK, Spoelstra N, Singh M, Borges V, Finlayson C, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant hormone therapy of breast cancers: dominance of tamoxifen agonist effects in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment 2008, epub 3/9/08.
• Harvell DM, Spoelstra NS, Singh M, Finlayson C, Phang T, Trapp S, Hunter L, Borges VB, Elias A, Horwitz KB, Richer JK. Molecular signatures of response to neoadjuvant endocrine therapies for breast cancer. Breast Cancer Research and Treatment 2008, epub 3/13/08.
• Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff, AC, Eisenberg PD, Lehman M, Adams BJ, Baum CM, Miller KD. A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-1816. Epub 2008 Mar 17.
• Elias AD, Kabos P, Bowles DW. Adjuvant Treatment of Breast Cancer. In: Finlayson, editor. Elsevier, in press.
• Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small ER/Her2-positive node negative breast cancer. Oncology (Williston Park) 2008; 22: 1270-1276.
• Harvell DME, Spoelstra N, Singh M, Finlayson C, Elias A, Horwitz KB, Richer JK. Breast cancer androgen receptors are implicated in anti-estrogen therapy failure. Endocrine Society 2007.
• Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. University of Colorado Mult-disciplinary tumor board: A Young Woman with a Small Estrogen Receptor-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score. Oncology (Williston Park) 2007; 21: in press.
• 136. Harvell DME, Spoelstra N, Singh M, Finlayson C, Elias A, Horwitz KB, Richer JK. Breast cancer androgen receptors are implicated in anti-estrogen therapy failure. Endocrine Society 2007.
• Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow W, Hudis C, Wolff AC, Ingle JN, Gandara DR, Elias AD, Livingston RB, Martino S. Intensive Dose-Dense Versus High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 2007; 25: 1677-1682.
• 84. Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow W, Hudis C, Wolff AC, Ingle JN, Gandara DR, Elias AD, Livingston RB, Martino S. Intensive Dose-Dense Versus High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol, in press.
• 52. Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Hardesty L, Elias A. University of Colorado Mult-disciplinary tumor board: A woman with primary breast cancer and a solitary sternal metastasis. Oncology 2006; 20: 1068-71, 1075, 1079-80.
• 3. Kelly K, Elias A. Treatment of small cell carcinoma of the lung. A. Elias only author 1998-2001. Since 2002, with Dr. Karen Kelly as first author. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006
• 4. Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001, 2002, 2003, 2004, 2005, 2006
• 5. Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004, 2005, 2006.
• 5. Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004, 2005, 2006.
• 134. Harvell DME, Richer JK, Spoelstra N, Singh M, Elias A, Horwitz KB. Estrogen-regulated genes involved in response to neoadjuvant therapy for breast cancer. Endocrine Society 2006.
• 135. Deprimo SE, Friece C, Huang X, Smeraglia J, Sherman L, Collier M, Baum C, Elias AD, Burstein HJ, Miller KD. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. Proc ASCO 2006; 24: 22s (A578).
• 83. Ramaswamy B, Elias AD, Kelbick N, Morrow M, Hauger M, Rhoades C, Kendra K, Allen J, Chen H, Eckhardt G, Shapiro CL. Phase II Trial of Bevazicumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin Cancer Res 2006; 12: 3124-3129.
• Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology 2005; 19: 278-287 passim
• 2005, 2006 Kelly K, Elias A. Treatment of small cell carcinoma of the lung. A. Elias only author 1998-2001. Since 2002, with Dr. Karen Kelly as first author. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006
• 2005, 2006 Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001, 2002, 2003, 2004, 2005, 2006
• 2005 2006 Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004, 2005, 2006.
• Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients with previously treated metastatic breast cancer (MBC). Proc ASCO 2005; 23: 19s (A563)
• AD Elias, KD Miller, HJ Burstein, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, M Collier, BJ Adams, CM Baum. Sunitinib malate (SU11248), a multitargeted tyrosine kinase inhibitor: safety and efficacy as second-line therapy in metastatic breast cancer. AACR: Advances in Breast Cancer Research: LaJolla, CA 9/23/05
• Richer JK, Harvell DME, Spoelstra NS, Singh M, Elias AD, Horwitz KB. Molecular changes in response to pre-operative endocrine therapy. Abstract 5080. SABCS, 12/05
• Harvell DME, Richer JK, Spoelstra N, Singh M, Elias A, Horwitz KB. Estrogen-regulated genes involved in response to neoadjuvant therapy for breast cancer. Endocrine Society 2006
• DePrimo SE, Friece C, Huang X, Smeraglia J, Sherman L, Collier M, Baum C, Elias AD, Burstein HJ, Miller KD. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. ASCO 2006.
• Ramaswamy B, Elias AD, Kelbick N, Morrow M, Hauger M, Rhoades C, Kendra K, Allen J, Chen H, Eckhardt G, Shapiro CL. Phase II Trial of Bevazicumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin Cancer Res 2006; in press
• Elias AD, Kabos P, Bowles DW. Adjuvant Treatment of Breast Cancer: Chapter 20. In: Finlayson, editor. Elsevier, in press.
• Elias AD. The Use of Molecular Profiles in the Management of Breast Cancer. In: Finlayson, editor. Elsevier, in press.
• Maki RG, Keohan ML, Undevia S, Livingston M, Cooney M, Elias A, Saulle M, Wright JJ, D’Adamo DR, Schuetze S. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; in press.
• Lamont EB, Landrum MB, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, Keating NL, McNeil1 BJ for the Cancer and Leukemia Group B. Differences in Clinical Trial Patients Attributes and Outcomes According to Enrollment Setting. J Clin Oncol 2009; in press.
• Elias AD, Kabos P, Bowles DW. Adjuvant Treatment of Breast Cancer: Chapter 20. In: Finlayson, editor. Elsevier, in press.
• Elias AD. The Use of Molecular Profiles in the Management of Breast Cancer. In: Finlayson, editor. Elsevier, in press.
• Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerroero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the Androgen Receptor in Breast Cancer and Preclinical Analysis of Enzalutamide. Breast Cancer Research 2014, in press.
• Fisher C, Diamond JR, Kounalakis N, Kabos P, Mayordomo J, Rabinovitch R, Murphy C, Finlayson C, Borges VF, Elias AD. The Integration of Locoregional with Systemic Adjuvant Therapy for Early Stage Breast Cancer: the Shifting Sands of Decision Making. Breast Cancer Management 2014, in press.
• NCCN Breast Cancer guidelines version 2014.1
• Gordon MA, D’Amato N, Gu H, Liu B, Elias A, Richer JK. The anti-androgen enzalutamide synergizes with trastuzumab and everolimus to inhibit breast cancer growth via distinct mechanisms. Endocrine Society 2015.
• Robin TP, Sams S, Elias AD. The significance of ovarian and intraperitoneal disease in women with breast cancer. Seminars in Oncology 2014, in press.
• Kabos P, Elias AD. Breast Diseases: A Year Book Quarterly comment on sHer2 in Gepar Quinto. Breast Diseases 2014, in press.
• Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs B, Heinz RE, Elias AD, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple negative breast cancer critically rely on androgen receptor and respond to Enzalutamide in vivo. Molecular Cancer Therapeutics 2014; in press.

Professional Memberships

• ASCO, Member
• SWOG, Member
• AACR, Member
• SARC, Member

Practice Locations

UCHealth Diane O'Connor Thompson Breast Center - Anschutz
1635 Aurora Ct
3rd Floor
Aurora, CO 80045
720-848-1030

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Internal Medicine, Board Certification (1983)
• Medical Oncology, Board Certification (1985)

Conditions & Treatments

• Cancers - Bone Cancer
• Cancers - Breast Cancer
• Cancers - Sarcoma
• Cancers